EGFR mutation testing: what is the best choice?
|
|
- Job McKenzie
- 8 years ago
- Views:
Transcription
1 EGFR? EGFR mutation testing: what is the best choice? Dekairelle Anne-France, PhD Center for Applied Molecular Technologies Prof GALA Jean-Luc, MD, PhD In response to ligand binding, EGFR is activated via dimerization and subsequent autophosphorylation of the tyrosine kinase domain Phosphorylation activates downstream pathways cell growth and proliferation UCL Dec 2010 EGFR-targeted therapies : TKI Advanced NSCLC : one disease, one treatment? Doublet chemotherapy has been a gold standard for years Panitumumab (Vectibix) Cetuximab (Erbitux) Trastuzumab (Herceptin) Zalutumumab Nimotuzumab Matuzumab. Iressa (Gefinitib) Tarceva (Erlotinib) Imatinib (Glivec) Lapatinib «One size fits all» therapy is not effective enough Cell growth Angiogenesis Invasion Metastasis Schiller JH, et al. NEJM 2002;346:92-98 EGFR in NSCLC? Response rate to EGFR TKIs Clinical benefits of EGFR-TKIs demonstrated in NSCLC BUT : Drug improvement in patients with lung cancer is not universal among patients. Clinical observation It is more effective in lung cancer patients with the following characteristics: - Asian patients - Females - Never smoked - Adenocarcinoma histology + Asian patients 1
2 Why study EGFR in NSCLC? Use of molecular genetics for EGFR: Rationale! Clinical benefits of EGFR-TKIs demonstrated in NSCLC BUT : Drug improvement in patients with lung cancer is not universal among patients. Clinical observation: It is more effective in lung cancer patients with the following characteristics: - Asian patients - females - never smoked - adenocarcinoma histology EGFR mutations have been discovered to be associated with response to EGFR inhibition Activating mutation in the EGFR underlying responsiveness of NSCL cancer to gefitinib (Lynch et al, NEJMed, 05/2004) EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy (Paez et al, Sciences, 06/2004) EGFR gene mutations are common in lung cancer from «never smokers» and are associated with sensitivity to gefitinib (Pao et al, PNAS, 09/2004) Maemondo M et al. N Engl J Med 2010; 362: EGFR mutation & treatment with an EGFR-TKI in non-asian patients Recurrent Mutations in NSCLC Reck M Expert Rev. Anticancer Ther. 10(6), (2010) 2
3 Basic Principle of Individualized Medicine Pneumologists/Oncologists, Pathologists, Labs Lung Cancer Anapath The case of (mutated) EGFR Epithelial Growth Factor Receptor Lab Global cohort of treated patients Non responders Responders: 12-15% Integrated chain From the patient to the result Patient selection Patient selection Pneumologist / oncologist Pneumologist / oncologist Sampling Sampling DNA Extraction DNA Extraction Analysis Analysis What type of sample? Issues? Integrated chain From the patient to the result Pathologist Identification of the tumor zone Main issue Small tumor & small sample!!! A wide range of samples Surgical Tumor (rare if early stage...) Paraffin-Embedded-Formalin-Fixed Biopsy Cytology Unfixed Fixed in alcohol (cytospins) Embedded in paraffin Frozen specimens Bronchiolo Alveolar Lavage: Very few cells! However sometimes effective!!!! Slides are properly labelled (internal codification number) 3
4 Integrated chain From the patient to the result Patient selection Pneumologist / oncologist 1 Colored slide + Biopsies & FFPE 10 to 12 white slides (5µ) Surgical sample 6 White slides (5µ) Sampling DNA Extraction Molecular Analysis Pathologist Geneticist / Mol Biologist EGFR : Gene organization Mutated EGFR gene: impact on the EGFR protein! Kinase domain Much stronger inhibition of phosphorylation in presence of TKI TK domain EGFR mutations in the kinase domain (exons 18 to 21)!! Acquired RESISTANCE mechanism!! T790M : change in the catalytic cleft of the EGFR TK domain Methionine substitution introduces a bulkier side chain, causing steric hindrance that is thought to interfere with binding of erlotinib * Mainly present in relapsed tumors after an initial response and secundary to EGFR-TKIs therapy * Accounts for ~50% acquired resistance to EGFR-TKIs L747S / D761Y / insertion exon 20 : Modest resistance Huang S et al. Clin Cancer Res 2004;10: by American Association for Cancer Research Zhang and Chang Int J Med Sci 4
5 Molecular methods? What are the molecular methods used to identify EGFR mutations in NSCLC? Sequencing Gold-Standard, complete BUT tedious, time consuming, not very sensitive PCR-RFLP RFLP + GeneScan Applied only on well identified mutations, tedious, costly Real-Time PCR Rapid and sensitive but only on well identified mutations SNP assay (pyrosequencing?, microarrays, ) Not yet published.but also on well identified mutations TheraScreen Assay - Commercialized...but only on well identified mutations - not flexible for techno improvement - not attractive in academic R&D laboratories What is our current EGFR workflow? What is our current EGFR workflow? Pre-screening 5
6 Protocol Scraping Visual slide quality assessment Scraping : + overnight proteinase K DNA extraction DNA quantification HRM on the LightCycler 480 Real-Time PCR System Purification (positive or doubtful HRM) Sequencing Manually DNA extraction Automated DNA quantification Use of the NucleoSpin Tissue Kits (Macherey-Nagel) In progress : comparative assays for an automated extraction via the EZ1 Biorobot (Qiagen) Nanodrop ND-1000 In the daily practice : fast screening! Primers Exon 18 DNA High throughput Screening phase (High Resolution Melting or HRM) WT: ~90% Mutated: ~10% Direct sequencing Do et al., BMC Cancer 2008, 8: Fragment Size : 199 pb agcccatgcc gtggctgctg gtccccctgc tgggccatgt ctggcactgc tttccagcat ggtgagggct gaggtgaccc ttgtctctgt gttcttgtcc cccccagctt gtggagcctc ttacacccag tggagaagct cccaaccaag ctctcttgag gatcttgaag gaaactgaat tcaaaaagat caaagtgctg ggctccggtg cgttcggcac ggtgtataag gtaaggtccc tggcacaggc ctctgggctg ggccgcaggg cctctcatgg tctggtgggg agcccagagt Mutation Identification 6
7 Primers Exon 19 Heideman et al., Cellular Oncology 2009, 31 : Primers Exon 20p Heideman et al., Cellular Oncology 2009, 31 : Fragment Size : 146 pb cggctccaca gccccagtgt ccctcacctt cggggtgcat cgctggtaac atccacccag atcactgggc agcatgtggc accatctcac aattgccagt taacgtcttc cttctctctc tgtcataggg actctggatc ccagaaggtg agaaagttaa aattcccgtc gctatcaagg aattaagaga agcaacatct ccgaaagcca acaaggaaat cctcgatgtg agtttctgct ttgctgtgtg ggggtccatg gctctgaacc tcaggcccac cttttctcat gtctggcagc tgctctgctc tagaccctgc tcatctccac atcctaaatg ttcactttct atgtctttcc Fragment Size : 122 pb catgcgaagc cacactgacg tgcctctccc tccctccagg aagcctacgt gatggccagc gtggacaacc cccacgtgtg ccgcctgctg ggcatctgcc tcacctccac cgtgcaactc atcacgcagc tcatgccctt cggctgcctc ctggactatg tccgggaaca caaagacaat attggctccc agtacctgct caactggtgt gtgcagatcg caaaggtaat cagggaaggg agatacgggg aggggagata aggagccagg atcctcacat gcggtctgcg ctcctgggat agcaagagtt tgccatgggg atatgtgtgt gcgtgcatgc agcacacaca cattccttta Primers Exon 20d Heideman et al., Cellular Oncology 2009, 31 : Primers Exon 21 Adapted from Heideman et al., Cellular Oncology 2009, 31 : Fragment Size : 97 pb catgcgaagc cacactgacg tgcctctccc tccctccagg aagcctacgt gatggccagc gtggacaacc cccacgtgtg ccgcctgctg ggcatctgcc tcacctccac cgtgcagctc atcacgcagc tcatgccctt cggctgcctc ctggactatg tccgggaaca caaagacaat attggctccc agtacctgct caactggtgt gtgcagatcg caaaggtaat cagggaaggg agatacgggg aggggagata aggagccagg atcctcacat gcggtctgcg ctcctgggat agcaagagtt tgccatgggg atatgtgtgt gcgtgcatgc agcacacaca cattccttta Fragment Size : 199 pb tggatcagta gtcactaacg ttcgccagcc ataagtcctc gacgtggaga ggctcagagc ctggcatgaa catgaccctg aattcggatg cagagcttct tcccatgatg atctgtccct cacagcaggg tcttctctgt ttcagggcat gaactacttg gaggaccgtc gcttggtgca ccgcgacctg gcagccagga acgtactggt gaaaacaccg cagcatgtca agatcacaga ttttgggctg gccaaactgc tgggtgcgga agagaaagaa taccatgcag aaggaggcaa agtaaggagg tggctttagg tcagccagca ttttcctgac accagggacc aggctgcctt cccactagct gtattgttta acacatgcag gggaggatgc tctccagaca ttctgggtga HRM protocole Primers : 0,15 µm - MgCl2 : 2,5 mm DNA : 10 to 15 ng Activation : 95 C 10 Amplification (50 cycles) : 95 C C 10 : Touchdown 1 /cycle the first 10 cycles - 55 C for the last 40 cycles 72 C 30 : recording of the data HRM : 97 C 1 40 C 1 70 C 1 95 C : Continuous Aquisitions : 25. Thus 25 acquisition/ C from 70 to 95 C Cooling : 40 C 30 Results ( ) Comparison HRM-sequence analysis (validation carried out on at least 40 samples) 58 % Insufficent DNA quality or quantity: no HRM nor sequence analysis! 4 DNA amount insufficient for sequencing but sufficient for HRM 8 Results comparison HRM and sequence analysis of exons 18 to Informative rate = 79.3 Discrepant results after HRM and sequence analysis 0 Concordance = Total number of samples received since 5/02/ Insuffisant DNA quality or quantity for HRM 26 HRM analysis (followed by selective sequence analysis of the "positive samples") 217 Informative rate = 89.3 a. HRM-negative samples 189 b. HRM-positive samples 28 % HRM-positive = 12.9 * Mutated samples % Mutated samples = exon 18 E709K; G719C 1 exon 19 del E746-A750 6 exon 19 del L747-S752; P753S 1 exon 19 del L747-E749; A750P 1 exon 19 del L747-S755 InsTRD 1 exon 20 R776G et exon 21 L861Q (double mutation) 1 exon 21 V851I 1 exon 21 L858R 6 exon 21 L861Q 1 Samples with HRM-detectable polymorphism * 9 % Irrelevant SNP = 4.1 7
8 Identification of EGFR Factors impacting on the success rate? Patients selection influence /Geographical influence: Comparison ( ) Patient selection? Quality of the pre-analytical step? (quality/quantity sample DNA) Analytic step (methodology) North South Lux TOTAL Nb samples (n=243) Unsatisfactory (test failure) HRM analysis Informative Rate 48 87, , ,29 a. HRM-negative samples Ana path Lab b. HRM-positive samples * Mutated samples % Mutated Samples 7 14,58 7 6,31 5 8,62 * Polymorphism % Irrelevant SNP 2 4,17 3 2,70 4 6,90 If St Luc only (n=33): Informative Rate: 97% - mutation rate 12% Identification of EGFR Factors impacting on the success rate? Influence of the analytical method Therascreen versus HRM (Preliminary data ) Patient selection? Quality of the pre-analytical step? (quality/quantity sample DNA) Analytic step (methodology) Ana path Lab Slides from the tumor Same DNA sample Sample HRM-Seq Therascreen 1 WT WT 2 WT WT 3 pos, L858R No Sample 4 WT WT 5 WT WT 6 WT WT 7 WT WT 8 pos, del , mut P753S exon 19 pos, del exon 19 9 WT WT 10 WT WT 11 onvoldoende DNA onvoldoende DNA 12 WT WT 13 WT WT 14 onvoldoende DNA WT 15 pos, del exon 19 pos, del exon WT WT 17 WT WT 18 WT WT 19 HRM pos Exon 21 (seq in progress) pos, L858R, exon WT WT 21 WT WT 22 WT WT 23 WT WT 24 WT WT 25 HRM pos Exon 20p (seq in progress) pos, Ins exon WT WT 27 WT WT 28 WT WT 29 WT WT 30 WT WT 31 HRM pos Exon 21 (seq in progress) WT 32 WT WT 33 WT WT Data from : Jessa Hospital Clinical Laboratory for Molecular Diagnostics Hasselt TheraScreen Allow to detect the more prevalent mutations (described until now) : 28 activating mutations 1 resistance mutation (T790M). List: 19 Del exon 19 T790M L858R L861Q G719X S768I 3 Ins exon 20 Based on a real-time PCR with the ARMS (Amplification refractory mutation system) and Scorpions technologies Sensitivity: 1% BUT limited to already well identified mutations!! Costs HRM (1/3) based on a cohort of 200 patients/year LC480 HMR Master (5*1mL) HTVA 480 euros Per well 10 µl Per well HTVA Analysis in triplicat Exons 18 to 21 (2 for 20) 6 controls (3- / 3+) 4 patients / series 0.96 euros HTVA 3 wells/amplicon & patients 5 amplicons per patients 90 wells/experiment 90*0.96 = 86.4 euros For one patient 86.4 / 4 = 21.6 HTVA Updated from data of Dr El Housni (Erasme) 8
9 Costs HRM (2/3) based on a cohort of 200 patients/year Plates (50/box) HTVA One plate For one patient 370 euros 7.4 euros Primers HTVA / synthesis ~26 euros Life Time : 3 years For one primer & 1 patient One analysis 7.4 / 4 = 1.85 HTVA 600 patients euros HTVA 2 primers / 5 amplicons Costs HRM (3/3) based on a cohort of 200 patients/year Sequencing Expected cases 10% Patients a year 200 Sequences 200*2/10 = 40 Patients in triplicate Price for 1 seq 40*3 = 120 seq 5 euros HTVA Price for seq in 1 year 600 euros HTVA For one patient (distributed on all patients) 3 HTVA For one patient 0.43 HTVA TOTAL HRM For one patient 28.9 TVA HRM + Sequencing included For a mutated sample 32 TVA Updated from data of Dr El Housni (Erasme) Updated from data of Dr El Housni (Erasme) Costs Therascreen Turn around time HRM analysis Limited component = Mix STD One kit : 500 µl - 5 µl for one well - 40 µl for one plate MAX 12.5 plates for one kit Number of patients / plate : 10 Price of 1 kit : euros HTVA TVA Price for 1 plate : 1206,3 TVA 10 patients / plate : 120,6 TVA / pt 5 patients / plate : 241,3 TVA 3 patients / plate : 402,1 TVA 2 patients / plate : 603,1 TVA 1 patient / plate : 1206,3 TVA Tu p.m.: We a.m.: We p.m.: Th a/p.m.: Fr a.m.: Scraping of the tumour zone DNA extraction (first part) DNA extraction (final steps) DNA quantification (Nanodrop) HRM analysis STOP for wild-type samples (~75%): 1.5 day DNA purification Cycle sequencing analysis Sequence analysis Report for suspected mutated samples: 3 days Start WT? Mut Updated from data of Dr El Housni (Erasme) Mo Tu We Th Fr Sa So Mo Tu We Th Fr Sa So Mo Tu Thanks for your attention Bonnes fêtes!! Prettige Feesten!! 9
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationThe following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
More informationSuccesses and Limitations of Targeted Cancer Therapy in Lung Cancer
Successes and Limitations of Targeted Cancer Therapy in Lung Cancer Kenichi Suda a, b Tetsuya Mitsudomi a a Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama,
More informationNon-Small Cell Lung Cancer
Non-Small Cell Lung Cancer in East tasia Chia-Chi (Josh) Lin, MD, PhD 林 家 齊 Director of Phase I Center, e Department of Oncology, National Taiwan University Hospital Clinical Associate Professor, Department
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationThe EGFR mutation and precision therapy for lung cancer
for lung cancer Outcomes in advanced lung cancer have seen meaningful improvement in the past decade thanks to new precision drug therapies. Because tumors usually develop resistance to the drugs, scientists
More informationGebruik van predictieve markers voor targeted therapy in de algemene praktijk
Gebruik van predictieve markers voor targeted therapy in de algemene praktijk Gerrit A. Meijer, MD, PhD Professor of Pathology Chair of the Department of Pathology VU Universtiy Medical Center Amsterdam
More informationApplications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities
Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities Vincent A. Miller, M.D. Foundation Medicine, Inc. AACR Annual Meeting 2012 Current Concepts session
More informationTargeted Therapies in Lung Cancer
Targeted Therapies in Lung Cancer I Edited by: Simona Carnio Thoracic Oncology Division - St Luigi Hospital Orbassano (TO) - Italy Silvia Novello Department of Oncology - University of Torino - Italy Why
More informationProposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer
31 May 2012 Proposal for Tyrosine Kinase Inhibitors for Non Small Cell Lung Cancer PHARMAC is seeking feedback on a proposal to: fund gefitinib (Iressa) as a first line treatment for patients with locally
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 9/1/2011 Most Recent Review Date (Revised): 1/27/2015 Effective Date: 11/2/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationOncology Insights Enabled by Knowledge Base-Guided Panel Design and the Seamless Workflow of the GeneReader NGS System
White Paper Oncology Insights Enabled by Knowledge Base-Guided Panel Design and the Seamless Workflow of the GeneReader NGS System Abstract: This paper describes QIAGEN s philosophy and process for developing
More informationRapid Review: EGFR gene mutation testing in patients with advanced NSCLC for access to Gefitinib for sector discussion
Rapid Review: EGFR gene mutation testing in patients with advanced NSCLC for access to Gefitinib for sector discussion June 2012 Key words: NSCLC, EGFR, EGFR-TKIs, New Zealand situation, personalised testing,
More informationTargeted agents in lung cancer: EGFR TKI and beyond
Targeted agents in lung cancer: EGFR TKI and beyond David CL Lam, MBBS, PhD, MD, FCCP, FACP, FRCP, FAPSR Clinical Assistant Professor Department of Medicine University of Hong Kong 13 Nov, 2014 The Changing
More informationCancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationCáncer de Pulmón n con Mutación de EGFR: Una Entidad Clínica y Patológica Distinta
Cáncer de Pulmón n con Mutación de EGFR: Una Entidad Clínica y Patológica Distinta Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Advanced NSCLC: chemotherapy has reached a therapeutic
More informationLung Cancer Research: From Prevention to Cure!
Lung Cancer Research: From Prevention to Cure! Ravi Salgia, M.D, Ph.D Associate Professor of Medicine Director, Thoracic Oncology Research Program Department of Medicine Section of Hematology/Oncology
More informationEGFR gene mutations Ex 19 Ex 21 Paez et al, Science 2004
Evolution of knowledge in NSCLC Pao and Girard, Lancet Oncology 2011 Fattori da considerare nella scelta terapeutica del NSCLC nel 2012 Stadio di malattia PS Età Comorbidità Compliance e desiderio del
More informationClinical development of AZD9291 in non-small cell lung cancer
Clinical development of AZD9291 in non-small cell lung cancer Rachael Lawrance (AstraZeneca) PSI One Day Meeting: The Innovative, Challenging and Diversified World of Respiratory Disease 13 Nov 2015 Overview
More informationFARMACI PERSONALIZZATI PER
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica FARMACI
More informationEGFR MUTATIONS IN NON-SMALL CELL LUNG CANCER: LOCAL EPIDEMIOLOGY AND CLINICAL IMPORTANCE
Rev. Med. Chir. Soc. Med. Nat., Iaşi 2015 vol. 119, no. 4 INTERNAL MEDICINE - PEDIATRICS ORIGINAL PAPERS EGFR MUTATIONS IN NON-SMALL CELL LUNG CANCER: LOCAL EPIDEMIOLOGY AND CLINICAL IMPORTANCE F. Rusu-Cordunean
More informationThe Cancer Patient Journey. Dr. Jaco Fourie
The Cancer Patient Journey Dr. Jaco Fourie The Cancer Patient Journey Prevention and health promotion Screening Diagnosis and staging Treatment Surveillance and survivorship End of life care The Cancer
More informationHarmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
More informationHER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
More informationData Analysis for Ion Torrent Sequencing
IFU022 v140202 Research Use Only Instructions For Use Part III Data Analysis for Ion Torrent Sequencing MANUFACTURER: Multiplicom N.V. Galileilaan 18 2845 Niel Belgium Revision date: August 21, 2014 Page
More informationMolecular analyses of EGFR: mutation and amplification detection
Molecular analyses of EGFR: mutation and amplification detection Petra Nederlof, Moleculaire Pathologie NKI Amsterdam Henrique Ruijter, Ivon Tielen, Lucie Boerrigter, Aafke Ariaens Outline presentation
More informationName of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC)
Name of Policy: Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer (NSCLC) Policy #: 468 Latest Review Date: October 2015 Category: Laboratory Policy Grade: B Background/Definitions:
More informationPNA BRAF Mutation Detection Kit
- PNA BRAF Mutation Detection Kit Catalog Number KA2102 50 tests/kit Version: 01 Intended for research use only www.abnova.com Introduction and Background Intended use The PNA BRAF Mutation Detection Kit
More informationEl papel de la anatomía patológica en oncología: presente y futuro. The role of pathological anatomy in oncology: present and future
El papel de la anatomía patológica en oncología: presente y futuro The role of pathological anatomy in oncology: present and future Federico Rojo Fundación Jiménez Díaz, Madrid All patients with same diagnosis:
More informationA disease of populations of cells that live, divide, invade and spread without regard to normal limits
1 Targeted Cancer Therapies Mark McKeage Medical Oncology Specialist Professor in Clinical Pharmacology 2 Cancer Definition- A disease of populations of cells that live, divide, invade and spread without
More informationREPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
More informationHow can we generate economic value from personalized medicine and big data analysis?
Estonian Health Innovation Forum 2015 Focus on Personalised Medicine How can we generate economic value from personalized medicine and big data analysis? Jonathan Knowles October 26, 2015 Tallinn, Viru
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationMedical Policy Manual. Date of Origin: August 2010. Topic: Molecular Analysis for Targeted Therapy of Non- Small Cell Lung Cancer (NSCLC)
Medical Policy Manual Topic: Molecular Analysis for Targeted Therapy of Non- Small Cell Lung Cancer (NSCLC) Section: Genetic Testing Policy No: 56 Date of Origin: August 2010 Last Reviewed Date: December
More informationAccurate and sensitive mutation detection and quantitation using TaqMan Mutation Detection Assays for disease research
PPLICTION NOTE Mutation Detection ssays ccurate and sensitive mutation detection and quantitation using Mutation Detection ssays for disease research In this research study, we addressed the feasibility
More informationKRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Original Policy Date
MP 2.04.43 KRAS Mutation Analysis in Non-Small Cell Lung Cancer (NSCLC) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationEvaluating the Efficiency of Targeted Designs for Randomized Clinical Trials
Vol. 0, 6759 6763, October 5, 004 Clinical Cancer Research 6759 Perspective Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials Richard Simon and Aboubakar Maitournam Biometric
More informationtargeted therapy a guide for the patient
targeted therapy FOR LUNG CANCER a guide for the patient TABLE OF CONTENTS lung cancer basics... 2-3 Gene changes... 4-5 Testing... 7-8 Targeted therapy... 9-11 Drugs Targeting EGFR... 12 Drugs Targeting
More informationIntroduction To Real Time Quantitative PCR (qpcr)
Introduction To Real Time Quantitative PCR (qpcr) SABiosciences, A QIAGEN Company www.sabiosciences.com The Seminar Topics The advantages of qpcr versus conventional PCR Work flow & applications Factors
More informationEpidermal Growth Factor Receptor Mutations in Patients with Non Small Cell Lung Cancer
Review Epidermal Growth Factor Receptor Mutations in Patients with Non Small Cell Lung Cancer Bruce E. Johnson and Pasi A. Jänne Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber
More informationMoving forward, where are we with Clinical Trials?
Moving forward, where are we with Clinical Trials? Dennis A. Wigle Division of Thoracic Surgery Mayo Clinic AATS/STS General Thoracic Surgery Symposium Sunday, April 27 th 2014 2012 MFMER slide-1 Where
More informationtreatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can
Shristi Pandey Genomics and Medicine Winter 2011 Prof. Doug Brutlag Chronic Myeloid Leukemia: A look into how genomics is changing the way we treat Cancer. Until the late 1990s, nearly all treatment methods
More informationMaintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
More informationMEDICAL POLICY EFFECTIVE DATE: 12/20/07 REVISED DATE: 12/18/08, 12/17/09, 02/17/11, 12/15/11, 12/20/12, 12/19/13, 02/19/15
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationMonoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.
Monoclonal Antibodies in Cancer Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc. Disclaimer I had nothing to do with Herceptin Using lessons learned in new antibody projects
More informationDevelopments in Biomarker Identification and Validation for Lung Cancer
Developments in Biomarker Identification and Validation for Lung Cancer Alexandre Passioukov, MD, PhD Alexandre.Passioukov@eortc.be Contents Introduction Lung cancer pathogenesis NSCLC treatment options
More informationNICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.
bring together all NICE guidance, quality standards and other NICE information on a specific topic. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More information1. Le mutazioni di KRAS hanno tutte lo stesso significato clinico?
EGFR downstream pathways KRAS domande frequenti ed importanti. Luca Mazzucchelli Istituto cantonale di patologia Locarno )'"* )-# %& # +%,!"# '( "#$ Anti-EGFR monoclonal antibodies (MoAbs) Cetuximab and
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationPCR was carried out in a reaction volume of 20 µl using the ABI AmpliTaq GOLD kit (ABI,
Supplemental Text/Tables PCR Amplification and Sequencing PCR was carried out in a reaction volume of 20 µl using the ABI AmpliTaq GOLD kit (ABI, Foster City, CA). Each PCR reaction contained 20 ng genomic
More informationSeminar N2 Targeted Therapies in Hospital Pharmacy One Problem, Two Views
Dr. Tilman Schöning Heidelberg University Hospital, Germany Seminar N2 Targeted Therapies in Hospital Pharmacy One Problem, Two Views Conflicts of interest Participation in Advisory Boards Amgen GmbH,
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical
More informationNon Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
More informationLung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
More informationPublic-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
More information( targeted therapy ) ( oncogenesis ) ( epidermal. growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( epidermal growth
2008 19 8-13 growth factor receptor tyrosine kinase inhibitor EGFR-TKI ) ( targeted therapy ) ( oncogenesis ) ( epidermal factor receptor monoclonal antibody EGFR-moAb ) growth factor monoclonal antibody
More informationBRCA1 / 2 testing by massive sequencing highlights, shadows or pitfalls?
BRCA1 / 2 testing by massive sequencing highlights, shadows or pitfalls? Giovanni Luca Scaglione, PhD ------------------------ Laboratory of Clinical Molecular Diagnostics and Personalized Medicine, Institute
More informationHigh-quality genomic DNA isolation and sensitive mutation analysis
Application Note High-quality genomic DNA isolation and sensitive mutation analysis Izabela Safin, Ivonne Schröder-Stumberger and Peter Porschewski Introduction A major objective of cancer research is
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationHow To Make Cancer A Clinical Sequencing
10 this time, it s Personal In what is an exciting era in the evolution of oncology treatment, this special feature by Deborah J. Ausman explores how Next-Generation Sequencing and Convergent Informatics
More informationApplication Guide... 2
Protocol for GenomePlex Whole Genome Amplification from Formalin-Fixed Parrafin-Embedded (FFPE) tissue Application Guide... 2 I. Description... 2 II. Product Components... 2 III. Materials to be Supplied
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationChanging Paradigms for evaluating costs and benefits of drug treatments. Deven Chauhan Health Economist Office of Health Economics London, UK
Changing Paradigms for evaluating costs and benefits of drug treatments Deven Chauhan Health Economist Office of Health Economics London, UK What do we mean by changing paradigms? Elevating pharmaceutical
More informationAdvances in RainDance Sequence Enrichment Technology and Applications in Cancer Research. March 17, 2011 Rendez-Vous Séquençage
Advances in RainDance Sequence Enrichment Technology and Applications in Cancer Research March 17, 2011 Rendez-Vous Séquençage Presentation Overview Core Technology Review Sequence Enrichment Application
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationDescription: Molecular Biology Services and DNA Sequencing
Description: Molecular Biology s and DNA Sequencing DNA Sequencing s Single Pass Sequencing Sequence data only, for plasmids or PCR products Plasmid DNA or PCR products Plasmid DNA: 20 100 ng/μl PCR Product:
More informationMechanisms of primary/secondary resistance to EGFR inhibitors
UNIVERSITY OF OF TORINO DEPARTMENT OF ONCOLOGY Mechanisms of primary/secondary resistance to EGFR inhibitors Silvia Novello University of Torino Italy Department of Oncology silvia.novello@unito.it www.womengainstlungcancer.eu
More informationLung Cancer Genomics and Patient Individualization
Lung Cancer Genomics and Patient Individualization Ming Sound Tsao, MD, FRCPC Qasim Choksi Chair in Lung Cancer Translational Research University Health Network OCI/PMH Leading Causes of Deaths (WHO) In
More informationPharmacogenomic Approaches. Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain
Pharmacogenomic Approaches Luis Paz-Ares Hospital Universitario Virgen del Rocio Seville, Spain Pharmacogenetics & Pharmacogenomics Medicine tailored to the individual Genetic information, including the
More informationDigital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE
Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE CRUK Stratified Medicine Initiative Somatic mutation testing for prediction of treatment response in patients with solid tumours:
More informationClinical Use of Molecular Diagnos@cs in the Treatment of Lung Cancer
Clinical Use of Molecular Diagnos@cs in the Treatment of Lung Cancer Tianhong Tina Li, MD, PhD (thli@ucdavis.edu) Associate Professor of Clinical Medicine, School of Medicine Disclosures Grants/Research
More informationIKDT Laboratory. IKDT as Service Lab (CRO) for Molecular Diagnostics
Page 1 IKDT Laboratory IKDT as Service Lab (CRO) for Molecular Diagnostics IKDT lab offer is complete diagnostic service to all external customers. We could perform as well single procedures or complex
More informationMolecular Diagnostics in Thyroid Cancer
Disclosure Nothing to disclose Jonathan George, MD, MPH Assistant Professor Head and Neck Oncologic & Endocrine Surgery Molecular Diagnostics in Thyroid Cancer Current Practices & Future Trends UCSF Medical
More informationMédecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN
Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification
More informationInnovation: Present Meets Future
Innovation: Present Meets Future SOCIAL INNOVATION Leading Innovation in the Cooperative Group Setting Craig Nichols, M.D. BEST OF SWOG Barlogie-Salmon Myeloma Committee Robert Z. Orlowski, M.D., Ph.D.
More informationGenomic Clinical Trials: NCI Initiatives
Genomic Clinical Trials: NCI Initiatives James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute National Cancer Advisory Board Washington, DC December
More informationAnalysis of gene expression data. Ulf Leser and Philippe Thomas
Analysis of gene expression data Ulf Leser and Philippe Thomas This Lecture Protein synthesis Microarray Idea Technologies Applications Problems Quality control Normalization Analysis next week! Ulf Leser:
More informationREFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC212DFR PUBLICAT ION DATE JUNE 2013 GSK1572932A (NON-SMALL CELL LUNG CANCER) GSK1572932A (NON-SMALL CELL LUNG CANCER) - Executive Summary GSK1572932A (MAGE-A3): Key Metrics in NSCLC Markets
More informationWHITE PAPER SEPT 2015
WHITE PAPER SEPT 2015 LIQUID BIOPSY FOR THE DETECTION AND MONITORING OF CANCER: ANALYSIS OF 96 HOTSPOT MUTATIONS VIA PLASMA DERIVED CIRCULATING TUMOR DNA PATHWAY GENOMICS CANCER AND SOMATIC MUTATIONS The
More informationTECHNICAL INSIGHTS TECHNOLOGY ALERT
TECHNICAL INSIGHTS TECHNOLOGY ALERT UNLOCKING BREAST CANCER TUMORS' DRUG RESISTANCE A troubling phenomenon in breast cancer treatment is that some patients tumors become resistant to treatments over time.
More informationAppendix 2 Molecular Biology Core Curriculum. Websites and Other Resources
Appendix 2 Molecular Biology Core Curriculum Websites and Other Resources Chapter 1 - The Molecular Basis of Cancer 1. Inside Cancer http://www.insidecancer.org/ From the Dolan DNA Learning Center Cold
More informationIndividualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing
Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But
More informationASCO Initiatives in Personalized Medicine. Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology
ASCO Initiatives in Personalized Medicine Richard L. Schilsky, MD, FACP, FASCO Chief Medical Officer American Society of Clinical Oncology Financial Disclosures No financial relationships to disclose.
More informationTreatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
More informationInstruction manual for product # PNAC-2001. Version 1.2
PNAClamp BRAF Mutation Detection Kit For in vitro diagnostic use Instruction manual for product # PNAC-2001 Version 1.2 Store at -20 C. Instruction Version: Ver. 1.2 Date of Revision: 2012 February 1 /
More informationSur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
More informationMetAction actionable targets in cancer metastasis from bed to bench to byte to bedside
MetAction actionable targets in cancer metastasis from bed to bench to byte to bedside Kjersti Flatmark MD PhD Departments of Tumor Biology and Gastroenterological Surgery, Oslo University Hospital PIs:
More informationLightCycler 480 Real-Time PCR System. High Resolution Melting: Optimization Strategies. Technical Note No. 1
LightCycler 480 Real-Time PCR System Technical Note No. 1 High Resolution Melting: Optimization Strategies High resolution melting (HRM) is a novel, closed-tube, post-pcr technique allowing genomic researchers
More informationBioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy
BioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy Soonmyung Paik 1 ; Gyungyub Gong 2 ; Yap Yoon Sim 3 ; Tae- You Kim
More informationTargeted therapies and brain metastases in lung cancer patients. Benjamin Besse, MD, PhD. Medical Oncologist. 19 septembre 2014
Targeted therapies and brain metastases in lung cancer patients Benjamin Besse, MD, PhD Medical Oncologist 19 septembre 2014 Targeted therapies and brain mets! Brain mets in NSCLC! Specific targeted therapies!
More informationHow To Get A Cell Print
QUICK CELL CAPTURE AND CHARACTERIZATION GUIDE FOR CELLSEARCH CUSTOMERS CellSave EDTA Blood sample Rare cell capture Enumeration Single protein marker Cell capture for molecular characterization CELLSEARCH
More informationGuideline Development The American Society of Clinical Oncology
Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary
More information